Icon-Brain

Healthcare Professionals

Learn more about the latest in technological innovations to ablate, necrotize or coagulate soft tissue in the brain.

Icon-Heart

Patients & Caregivers

Find out more about minimally invasive brain surgery technology for you or your loved one.

NEUROBLATE® SYSTEM

NeuroBlate® is the only minimally invasive, robotic, laser thermal therapy tool that uses MRI-guided surgical ablation technology designed specifically for use in the brain.

The Minimally Invasive Surgical Choice

NeuroBlate provides precise and maximal brain lesion ablation for patients without the invasiveness of an open neurosurgical procedure. The precise nature of the procedure helps lessen the likelihood of harm to nearby healthy tissue.1

NeuroBlate offers hope and healing to patients suffering from a wide range of neurological lesions, including brain tumors, radiation necrosis, and epileptic foci.

EXCLUSIVE TECHNOLOGIES

NeuroBlate delivers a comprehensive, full solution laser ablation system that includes software, disposables, and hardware.

TruTemp Technology

TruTemp Technology


Provides confidence in the accuracy of the ablation zone and added safety assurance.

NeuroBlate Fusion Software

NeuroBlate Fusion Software


Allows neurosurgeons to plan, deliver, and monitor MRI-guided robotic laser thermal therapy.

NeuroBlate Optic Laser Probe

NeuroBlate Optic Laser Probe


The first and only commercially available laser probe with fiber optic controlled cooling.

CLINICAL RESEARCH & TRIALS

Our commitment to clinical research is an essential and integral part of our mission and is demonstrated in our clinical trial work.

Icon-Clinical Trials

Active Clinical Trials

The Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate® System (LAANTERN) Prospective Registry is currently enrolling eligible patients.

Icon-Clinical Bibliography

LITT Evidence

The cumulative utilization of LITT over time has been steadily increasing for metastatic tumor, primary tumor, radiation necrosis, and epileptic foci.

FIND A PHYSICIAN

A Minimally Invasive Surgical Option

To locate physicians currently using the NeuroBlate System, please click here.

Please note, NeuroBlate is available in the U.S. and Canada only.

RECENT NEWS

Press Release

Monteris Medical Announces Position Statements Issued on Laser Interstitial Thermal Therapy

Monteris Medical announced today that position statements supporting the use of laser interstitial thermal therapy (LITT) for people with brain tumors and drug-resistant epilepsy have been issued by the American Association of Neurological Surgeons (AANS), the Congress of Neurological Surgeons (CNS), and the American Society of Stereotactic and Functional Neurosurgery (ASSFN).

Press Release

Monteris Medical Announces Health Care Service Corporation Policy Coverage for its NeuroBlate® System Laser Interstitial Thermotherapy for Brain Tumors and Epilepsy

Monteris Medical, the leader in MRI-guided laser interstitial thermotherapy (LITT or laser ablation), announced today that health insurance provider Health Care Service Corporation (HCSC), one of the largest independent licensees of Blue Cross and Blue Shield Association® (BCBS), has updated its medical coverage policy allowing access to the minimally invasive laser ablation procedure for brain tumors and epilepsy when medically necessary.

Press Release

Monteris Medical Announces Publication of First Prospective Multicenter Study of Minimally Invasive Laser Ablation for Drug Resistant Epilepsy

Monteris Medical announced today the publication of results from a multicenter clinical study with its NeuroBlate® System for the treatment of drug resistant epilepsy have been published in the peer-reviewed journal Epilepsy Research. The paper describes data from the LAANTERN prospective multicenter registry, sponsored by Monteris Medical.

  1. Rennert RC, Khan U, Barktek J Jr et al. Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): procedural safety and hospitalization. Neurosurgery. published online: May 11, 2019. (doi: 10.1093/neuros/nyz141)